BASEL, Switzerland — Novartis on Thursday morning named Naomi Kelman head of the Novartis OTC division, effective March 2. She will report directly to Joseph Jimenez, Novartis CEO.
The Novartis OTC and animal health businesses will become separate Novartis divisions, in addition to the pharmaceuticals, Sandoz (generics), vaccines and diagnostics divisions. As previously announced, following the completion of the merger between Novartis and Alcon, CIBA Vision and Novartis ophthalmic medicines will be merged into the new Alcon eye care division of Novartis.
Until the close of the Alcon transaction, George Gunn will continue to manage the CIBA Vision business. Gunn also will assume his new role as head of animal health on March 2. Gunn additionally will become responsible for corporate social responsibility for Novartis, a move that elevates CSR to the executive committee level.
"With the upcoming Alcon merger, we have decided to put additional focus on two important businesses, which today comprise the consumer health division — OTC and animal health — by streamlining and simplifying our decision-making process," Jimenez said. "Naomi's experience in consumer businesses, combined with her drive for results make her well-suited to run our OTC business. George Gunn's extensive experience in animal health will increase the focus and growth prospects for this business."
Kelman joins Novartis from Johnson & Johnson, where she held several leadership roles within both the consumer and medical device and diagnostic sectors.
For financial reporting purposes, the Novartis OTC and Novartis animal health businesses will continue to be communicated under the umbrella of Novartis Consumer Health. Financial pro-formas of the new Consumer Health and Alcon divisions — including CIBA Vision and Novartis ophthalmic medicines — will be published following the merger with Alcon. Until then, the existing segmental presentation of financial results will continue, the company stated.